FI750941A7 - - Google Patents

Download PDF

Info

Publication number
FI750941A7
FI750941A7 FI750941A FI750941A FI750941A7 FI 750941 A7 FI750941 A7 FI 750941A7 FI 750941 A FI750941 A FI 750941A FI 750941 A FI750941 A FI 750941A FI 750941 A7 FI750941 A7 FI 750941A7
Authority
FI
Finland
Application number
FI750941A
Other languages
Finnish (fi)
Inventor
John B Glen
Roger James
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Ltd filed Critical Ici Ltd
Publication of FI750941A7 publication Critical patent/FI750941A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI750941A 1974-03-28 1975-03-27 FI750941A7 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1373974A GB1472793A (en) 1974-03-28 1974-03-28 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
FI750941A7 true FI750941A7 (enExample) 1975-09-29

Family

ID=10028495

Family Applications (1)

Application Number Title Priority Date Filing Date
FI750941A FI750941A7 (enExample) 1974-03-28 1975-03-27

Country Status (22)

Country Link
US (2) US4056635A (enExample)
JP (1) JPS50154410A (enExample)
AU (1) AU502164B2 (enExample)
BE (1) BE827290A (enExample)
CA (1) CA1038764A (enExample)
DE (1) DE2513797C2 (enExample)
DK (1) DK128675A (enExample)
DO (1) DOP1980002892A (enExample)
FI (1) FI750941A7 (enExample)
FR (1) FR2265357B1 (enExample)
GB (1) GB1472793A (enExample)
HK (1) HK34380A (enExample)
IE (1) IE40839B1 (enExample)
IL (1) IL46899A (enExample)
KE (1) KE3052A (enExample)
MY (1) MY8100111A (enExample)
NL (2) NL183079C (enExample)
NO (1) NO751076L (enExample)
NZ (1) NZ177023A (enExample)
PH (1) PH13553A (enExample)
SE (1) SE7503542L (enExample)
ZA (1) ZA751806B (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005001A (en) * 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
HU223343B1 (hu) * 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20020173547A1 (en) 1994-03-22 2002-11-21 Jones Christopher Buchan Pharmaceuticals compositions
US5731355A (en) * 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
MY113046A (en) * 1994-03-22 2001-11-30 Astrazeneca Uk Ltd Pharmaceutical compositions
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
IT1269977B (it) 1994-07-01 1997-04-16 Archimica Spa Purificazione del propofol
IT1270093B (it) 1994-09-28 1997-04-28 Zambon Spa Processo per la purificazione di 2,6-diisopropilfenolo
CN100512877C (zh) * 1995-03-17 2009-07-15 曾尼卡有限公司 无菌医药组合物
CN1106192C (zh) * 1995-03-17 2003-04-23 曾尼卡有限公司 含2,6－二异丙基苯酚和乙二胺四乙酸盐的水包油型乳液
AU6708096A (en) * 1995-09-18 1997-04-09 Vesifact Ag Propofol nanodispersions
DE69637441T2 (de) * 1995-10-17 2009-03-05 Jagotec Ag Verabreichung unlöslicher arzneistoffe
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
CH692322A5 (it) * 1997-05-26 2002-05-15 Westy Ag Formulazione iniettabile limpida di Propofol.
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
DE19757224A1 (de) 1997-12-22 1999-07-01 Bayer Ag Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation
CA2319810C (en) * 1998-02-10 2008-12-23 Gensia Sicor Inc. Propofol composition containing sulfite
CA2320807C (en) * 1998-02-11 2011-01-18 Research Triangle Pharmaceuticals Method and composition for treatment of inflammatory conditions
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
CA2333648C (en) 1998-05-29 2008-10-21 Rtp Pharma Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
AU759641B2 (en) 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6150423A (en) 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
BR9915738A (pt) 1998-11-20 2001-10-02 Rtp Pharma Inc Micropartìculas estabilizadas em fosfolipìdeos dispersìveis
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
ES2261210T3 (es) * 1999-06-21 2006-11-16 Kuhnil Pharmaceutical Co., Ltd. Comoposicion anestesica para inyeccion intravenosa que comprende propofol.
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
KR100386397B1 (ko) * 2000-04-19 2003-06-02 센츄론(주) 투명한 프로포폴 주사제
WO2001080828A2 (en) 2000-04-20 2001-11-01 Rtp Pharma Inc. Improved water-insoluble drug particle process
WO2001097779A2 (en) 2000-06-16 2001-12-27 Rtp Pharma Inc. Improved injectable dispersions of propofol
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
CA2420597C (en) 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
AU2001259099B2 (en) * 2001-02-22 2005-12-22 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
JP4127757B2 (ja) * 2001-08-21 2008-07-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信システム、通信端末装置、及びバースト信号送信方法
GB0120702D0 (en) * 2001-08-24 2001-10-17 Maelor Pharmaceuticals Ltd Anaesthetic formulations
CA2459125A1 (en) 2001-09-26 2003-04-03 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
GB0124071D0 (en) * 2001-10-08 2001-11-28 Kbig Ltd Improvement in the administration of high boiling point aneasthetics
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
ES2325918T3 (es) * 2001-12-28 2009-09-24 Eisai Corporation Of North America Formulaciones farmaceuticas de base acuosa de profarmacos de propofol solubles en agua.
JP3931680B2 (ja) * 2002-02-18 2007-06-20 株式会社日本自動車部品総合研究所 車両の直進判別装置
US20040220283A1 (en) * 2002-07-29 2004-11-04 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
NZ538255A (en) * 2002-07-29 2006-11-30 Transform Pharmaceuticals Inc Aqueous 2,6-diisopropylphenol pharmaceutical compositions
EP1556022A4 (en) * 2002-10-29 2010-03-10 Transform Pharmaceuticals Inc Aqueous 2,6-diisopropylprophenol-containing pharmaceutical compositions
CA2503956A1 (en) * 2002-10-29 2004-05-13 Transform Pharmaceuticals, Inc. Propofol with cysteine
NZ539834A (en) 2002-11-26 2007-08-31 Maruishi Pharma Isoindoline derivatives
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) * 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
ITMI20032054A1 (it) * 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
DK1706128T3 (da) 2003-12-08 2010-10-04 Cpex Pharmaceuticals Inc Farmaceutiske sammensætninger og fremgangsmåder til insulin-behandling
WO2005077337A2 (en) * 2004-02-05 2005-08-25 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
BRPI0612071A2 (pt) * 2005-06-14 2010-10-19 Baxter Int formulações farmacêuticas para minimizar interações entre fármacos
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US20100048732A1 (en) * 2006-05-30 2010-02-25 Emala Sr Charles W Method of mediating Airway Smooth Muscle Construction Due to Airway Irritation
WO2008008492A2 (en) * 2006-07-13 2008-01-17 University Of Iowa Research Fdtn. Hydrofluoroalkyl phenols having anesthetic properties
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
ATE540010T1 (de) 2007-05-09 2012-01-15 Pharmacofore Inc Therapeutische verbindungen
PL2146946T3 (pl) * 2007-05-09 2011-04-29 Pharmacofore Inc (-)-Stereoizomer 2,6-di-sec-butylofenolu i jego analogi
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US20090198145A1 (en) * 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
US20180022698A1 (en) 2014-10-16 2018-01-25 The Board Of Trustees Of The Leland Stanford Junior University Novel methods, compounds, and compositions for anesthesia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2104412A (en) * 1931-12-29 1938-01-04 Standard Oil Dev Co Alkyl phenols
GB831071A (en) 1956-04-26 1960-03-23 British Schering Ltd Analgesic compounds
GB803080A (en) 1956-07-06 1958-10-15 Scient Oil Compounding Co Inc Bacteriostatic compositions
US2966442A (en) * 1956-09-20 1960-12-27 American Home Prod Antibiotic compositions
US3476838A (en) * 1958-12-04 1969-11-04 Ethyl Corp Di(2,6-diisopropylphenyl) mono halo phosphite or (thio) phosphate
US3067106A (en) * 1959-04-07 1962-12-04 Foundation For Prosthetic Res Skin treating method and composition

Also Published As

Publication number Publication date
IE40839B1 (en) 1979-08-29
NL7503696A (nl) 1975-09-30
AU502164B2 (en) 1979-07-12
DE2513797C2 (de) 1987-07-30
NL183079C (nl) 1988-07-18
NL930084I1 (nl) 1993-09-16
CA1038764A (en) 1978-09-19
NO751076L (enExample) 1975-09-30
FR2265357B1 (fr) 1978-08-04
FR2265357A1 (fr) 1975-10-24
PH13553A (en) 1980-06-26
MY8100111A (enExample) 1981-12-31
US4056635A (en) 1977-11-01
NZ177023A (en) 1984-09-28
BE827290A (fr) 1975-09-29
SE7503542L (enExample) 1975-09-29
US4452817A (en) 1984-06-05
NL930084I2 (nl) 1994-10-17
IE40839L (en) 1975-09-28
GB1472793A (en) 1977-05-04
JPS50154410A (enExample) 1975-12-12
HK34380A (en) 1980-07-01
DE2513797A1 (de) 1975-10-09
ZA751806B (en) 1976-02-25
KE3052A (en) 1980-06-27
AU7953675A (en) 1976-09-30
IL46899A (en) 1978-03-10
IL46899A0 (en) 1975-06-25
DK128675A (de) 1975-09-29
DOP1980002892A (es) 1989-10-04

Similar Documents

Publication Publication Date Title
AU465373B2 (enExample)
AR199134A1 (enExample)
AU1893276A (enExample)
BG20062A1 (enExample)
BG20149A1 (enExample)
AU479427A (enExample)
AU479523A (enExample)
AU479624A (enExample)
AU479870A (enExample)
AU480070A (enExample)
AU480148A (enExample)
AU480401A (enExample)
AU480465A (enExample)
AU480559A (enExample)
AU480783A (enExample)
AU480879A (enExample)
AU481045A (enExample)
AU481360A (enExample)
AU481917A (enExample)
AU482236A (enExample)
AU482244A (enExample)
AU482365A (enExample)
BE525532A (enExample)
BE829579A (enExample)
BE829996A (enExample)

Legal Events

Date Code Title Description
FC Application refused

Owner name: IMPERIAL CHEMICAL INDUSTRIES LIMITED